Piper Jaffray believes Argenx’s lead drug efgartigimod is ‘best-in-class’

Piper Jaffray analyst Edward Tenthoff continues to believe Argenx’s lead drug efgartigimod is a “best-in-class anti-FcRn antibody with a biological mechanism amenable to treating several autoimmune diseases characterized by upregulation of IgG.” Further, the analyst is looking forward to the May 16 R&D Day to “highlight Argenx’s exceptional drug discovery capabilities with introduction of ARGX-117 and ARGX-118.” Tenthoff reiterated an Overweight rating and $161 price target on Argenx shares.
https://thefly.com/landingPageNews.php?id=2845739